

# APAC Expert Consensus Guideline in BRAFV600E mutant mCRC: Perspectives from Asia

Organised by Asia GI Oncology Research Group (AGIORG)

WITH:



A/Prof Iain Tan  
Singapore



Prof Brigette Ma  
Hong Kong



A/Prof Hung-Chih Hsu  
Taiwan

We invite healthcare professionals with an interest in gastrointestinal cancers to join us and discuss the latest APAC Consensus Guidelines publication in BRAFV600E mutant mCRC with the co-authors.

**Thursday 14th November 2024 18:00 - 18:50 (SG/HK/TW)**  
**Online Webinar**

TIME	TOPIC	PRESENTER
18:00	Introduction & Objectives	A/Prof Iain Tan
18:05	Review of current evidence in the treatment of BRAF mutant mCRC in the context of Asia	Prof Brigette Ma
18:15	Case Study Presentation - MSI-high/BRAF mutant mCRC in the real world	A/Prof Hung-Chih Hsu
18:25	Panel discussion on BRAF mutant mCRC case study and Q&A	All
18:45	Close & key take-aways	A/Prof Iain Tan

To register,  
**SCAN** this QR code



**CLICK HERE  
TO REGISTER**



## A/Prof Iain Tan, National Cancer Centre, Singapore

A/Prof Iain Tan is a Senior Consultant Medical Oncologist and the Director of Research for the Division of Medical Oncology. He is a colorectal medical oncologist and NMRC clinician scientist-senior investigator awardee. His research spans translational research, clinical trials, and Public Health. He is a principal Investigator of the Laboratory of Applied Cancer Genomics at the Genome Institute of Singapore, A-Star, and faculty at CSCB, Duke-NUS. He is the clinical chair of Singapore's colorectal cancer large collaborative grant program ColoSCRIPT. A/Prof Iain collaborates widely with clinicians, scientists, and public health practitioners. He leads several data science efforts in Singhealth and is the platform lead for Tissue bank/Data & Population Health and Impact for Singapore Translational Cancer Consortium.

A firm believer in team science, together with his partners, he has published widely in top journals (e.g., Nature, Nature Genetics, JAMA, Cancer Discovery) in CRC, public health, and data science.



## Prof Brigette Ma, Chinese University of Hong Kong, Hong Kong

Dr Brigette Ma is currently Professor and Honorary Consultant at the Department of Clinical Oncology, Chinese University of Hong Kong (CUHK), Medical Director of the Phase I Clinical Trial Centre (Oncology) and Chair of the NTEC-CUHK ethics committee for phase 1 studies. She received her undergraduate degree with Honours at Monash University, Australia, and was awarded Fellow of the Royal Australasian College of Physicians, Fellow of Hong Kong College of Physicians, and Doctor of Medicine (CUHK). She underwent training in Medical Oncology at the Peter MacCallum Cancer Institute, Melbourne, and was Research Fellow at the Princess Margaret Hospital, Toronto, Canada. She has published over 200 peer-reviewed papers. Notably, she had been a Faculty member of the European Society of Medical Oncology (ESMO) in Gastrointestinal Cancer, and was a member of the Consensus Working Group for the management of metastatic colorectal cancer; executive member of the National Cancer Institute (Bethesda, USA) Head and Neck Cancer Steering Committee - Clinical Trials Planning Group on Nasopharyngeal Cancer, Co-chair of Widely Metastatic Group; and mentor and committee member of the Women in Cancer Research of the American Association of Cancer Research. Her other current roles include member of the Joint Scientific Committee for Phase 1 Clinical Trials, Centre of Health Protection, Hong Kong Hospital Authority; Track Chair/ member of the Scientific Committee American Association of Cancer Research, ESMO congresses. She is co-Scientific chair of the ESMO-Asia conference in Singapore and co-chairs for some ESMO advanced course/ workshops concerning early drug development. She is Associate Editor of Oral Oncology and is a member of the Editorial Board for ESMO Open (GI) and Clinical Colorectal Cancer, amongst other journals.



## A/Prof Hung-Chih Hsu, Chang Gung Memorial Hospital, Taiwan

Dr Hung-Chih Hsu is an Associate Professor and attending physician of Division of Hematology/Oncology, Chang Gung Memorial Hospital. A/Prof Hsu graduated from the Medical Department of Taipei Medical University, and later obtained his PhD degree from the Graduate Institute of Clinical Medicine, Chang Gung University. He was a research fellow in the Department of Basic Science, UC Davis Medical Cancer Center. His clinical focus is on colorectal where he has been involved in several key studies, including BREAKWATER, KEYNOTE-177 and DESTINY-CRC02.

Endorsed by

Independent support from



中華民國大腸直腸外科醫學會  
SOCIETY OF COLON AND RECTAL SURGEONS, TAIWAN



LABORATOIRES  
**Pierre Fabre**